The Wall Street Journal’s Science Journal correspondent today “bestows holiday gifts” (sub req’d) on researchers, drugs, and other approaches that have advanced health and medicine, or set it back.
Given yesterday’s discussion of the failed efficacy trial for black cohosh, I chuckled at this one:
To the herbal supplement called saw palmetto, taken by some 2.5 million men in the U.S., which failed to help urinary problems any better than a placebo: a framed copy of the 1994 law that lets dietary supplements be sold even if there is no evidence of their efficacy.
The funny thing is that I wrote about the serious issues on this particular study back at the old blog in February.
So, I’ll repeat what I said then: if the US NIH is going to spend millions of dollars on randomized, controlled trials of herbal/botanical medicines or supplements, some effort would be better invested first in the appropriate basic science and pharmacokinetic studies necessary for appropriate dosing with a scientifically-qualified supplement exhibiting quantified and predictable bioavailability of the key active principle(s)…or to determine whether a trial is even indicated by the accumulated evidence.
Until these conditions are addressed, I predict a continued string of negative outcomes in clinical botanical trials, even for agents that appear very promising based on traditional uses.